Molecular Templates Announces Dosing of First Patient in Phase 1 Expansion Study of MT-3724 in Diffuse Large B-Cell Lymphoma (DLBCL)
Molecular Templates, Inc. (MTEM)
Last molecular templates, inc. earnings: 11/12 05:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mtem.com/investor-relations
Company Research
Source: GlobeNewswire
- Maximum Tolerated Dose of MT-3724 Identified AUSTIN, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), today announced the dosing of the first patient in a Phase 1 expansion study of MT-3724, a first-generation ETB that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias. Strong evidence of anti-tumor activity in heavily pre-treated patients has been observed in Part 1 of the study. “MT-3724 has shown activity in heavily pre-treated DLBCL patients with a median of greater than four prior therapies in the dose escalation portion of this study,” said Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “We are pleased to begin dosing patients in the expansion cohort, which is designed to further characterize the efficacy and response rates in these difficult t
Show less
Read more
Impact Snapshot
Event Time:
MTEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTEM alerts
High impacting Molecular Templates, Inc. news events
Weekly update
A roundup of the hottest topics
MTEM
News
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer PatieAcquire Media Monitor
- Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer PatieGlobeNewswire
- Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business UpdateGlobeNewswire
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement [Yahoo! Finance]Yahoo! Finance
- Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase AgreementGlobeNewswire
MTEM
Earnings
- 11/13/23 - Beat
MTEM
Sec Filings
- 5/6/24 - Form EFFECT
- 5/3/24 - Form 424B3
- 4/29/24 - Form SC
- MTEM's page on the SEC website